AzTrials
AzTrials

Coronary Artery DiseaseNCT05933473

Clinical and Procedural Outcomes of Ostial Left Anterior Descending Artery Intervention With or Without Crossover to Left-main

A study testing Percutaneous coronary intervention in people with Coronary Artery Disease, run by Assiut University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Prospective interventional study evaluating clinical and procedural outcomes of patients with ostial left anterior descending artery lesion PCI alone or crossover with left main artery Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
Coronary Artery Disease
What is being tested?
Percutaneous coronary intervention
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
72 participants
Where
No sites listed yet
Study dates
Jul 2023to Jul 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Patients with Significant ostial LAD >50% stenosis within 5mm from ostium
  • Either CCS (ongoing symptoms despite medical therapy) or ACS patients.
  • De-novo lesions.

Who cannot join

  • Those with coronary angiography results such as: (significant disease of the LM more than 40% or ostial LCX greater than 50%).
  • Patients with protected LM.
  • In adherence to a dual antiplatelet regimen by enrolled patients within the first 12 months after the procedure.

Trial locations and contacts

No sites are listed yet.

Mohamed AN AbdEl-Reheem, MSC contact

01119535430

m.naserdrea3@aun.edu.eg

Aly M Tohamy, MD contact

01006258877

ali.tohamy@gmail.com

About this study

Prospective interventional study evaluating clinical and procedural outcomes of patients with ostial left anterior descending artery lesion PCI alone or crossover with left main artery

Read the detailed description

Aim of the work:

  1. Evaluate the clinical and procedural outcomes in patients undergoing percutaneous intervention (PCI) for ostial left anterior descending (LAD) lesions while comparing the outcomes between those treated with a stent crossing over (CO) to the left main (LM) versus ostial stenting (OS) alone.
  2. Define predictors of success in Ostial LAD lesion PCI.

Patients and methods:

1)Patients:

Inclusion criteria:

  1. Patients with Significant ostial LAD >50% stenosis within 5mm from ostium
  2. Either chronic coronary syndrome (CCS) (ongoing symptoms despite medical therapy) or acute coronary syndrome (ACS) patients.
  3. De-novo lesions.

Exclusion Criteria:

  1. Those with coronary angiography results such as: (significant disease of the LM more than 40% or ostial left circumflex (LCX) greater than 50%).
  2. Patients with protected LM.
  3. In adherence to a dual antiplatelet regimen by enrolled patients within the first 12 months after the procedure.

Methods:

It is prospective cohort study on patients in Assiut university heart hospital catheterization lab. with ostial LAD lesion (median, 0.1.0) that will include baseline demographic, clinical, and angiographic data.

All patients will be thoroughly informed about the procedure's possible risks and benefits, as well as alternative therapeutic choices prior to the intervention, and obtained signed consent from all participants.

In all cases, percutaneous coronary interventions and stenting will be performed according to standard techniques either trans-radial or transfemoral approach.

All patients pre-treated with dual antiplatelet therapy, including aspirin and loading dose of either clopidogrel or ticagrelor.

Unfractionated heparin will be given to all patients during the procedure with a target activated clotting time of >250 seconds.

Two main strategies for treating ostial LAD lesions will be used and analyzed in this study:

  1. Crossover stenting (CO) from the LM into the LAD, using standard provisional bifurcation techniques and proximal stent optimization (POT), where post dilatation was typically performed.
  2. Ostial stenting of the LAD (OS) with no crossover back to the LM. The choice of the technique and the use of intravascular imaging (IVUS) depends on the discretion of the treating interventional cardiologist.
  • Patients included in our study will be subjected to:
  1. Detailed History.
  2. General and complete cardiac examination.
  3. 12-Leads ECG.
  4. Detailed Echocardiography. \ 5)Coronary angiography findings including:
  5. Quantitative angiographic measurements:
  6. Reference diameter (mm).
  7. Diameter stenosis (%).
  8. Lesion length and distance from LAD ostium(mm).
  9. Medina classification.
  10. Bifurcation angle.
  11. Techniques used:
  12. Ostial LAD stenting.
  13. Crossover with LM. C. IVUS or angiography guided PCI.

Basic IVUS Measurement

The following basic measurements may be made with IVUS:

  1. Minimum lumen diameter (MLD): the shortest diameter via lumen's center.
  2. Minimum lumen area (MLA): the smallest area via the lumen's center.
  3. Stenosis area: (reference lumen area - stenosis lumen area)/reference lumen area.
  4. Plaque burden: (EEM area - lumen area) / EEM area .
  5. Contrast volume (ml) E. Fluoroscopy time (min.) Data will be gathered during hospital admission and follow-up. In-hospital mortality and morbidity will be documented.

Follow up:

During the hospital admission:

Both techniques used by our operators in these cases will be overviewed and evaluated as regarding:

  1. Angiographic success in target vessel defined as (residual stenosis ≤ 30% and TIMI flow grade 3) and side branch (SB) angiographic success (residual stenosis ≤ 50% and TIMI flow grade 3).
  2. Procedural Success A successful PCI should achieve angiographic success without in-hospital major clinical complications (e.g., cardiac death, target vessel related MI, emergency coronary artery bypass surgery) during hospitalization
  3. Clinical Success in the short term, a clinically successful PCI includes anatomic and procedural success with relief of signs and/or symptoms of myocardial ischemia after the patient recovers from the procedure.

Information about the in-hospital outcome will be obtained from an electronic clinical database for patients maintained at our institution and by review of hospital records for those discharged to referring hospitals.

Short term follow up (after 6 months):

  1. Per our institutional protocol, clinical follow-up will be performed by physicians in outpatient clinic after 4 months.
  2. Control coronary angiography will be scheduled at 6 months to all cases.
  3. Information on the occurrence of cardiac death, target vessel related myocardial infarction or repeated revascularization during period of follow-up will be collected by consulting our institutional electronic database and by contacting referring physicians and institutions and all living patients.
Being tested
Percutaneous coronary intervention
Medical subject headings
Coronary Artery Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Percutaneous coronary interventionProcedure or surgery

    percutaneous intervention to oseal LAD with or without LM stenting

Study groups in NCT05933473
Study groupRoleWhat they receive
LM-LAD (Crossover stenting (CO))Active comparatorCrossover stenting (CO) from the LM into the LAD, using standard provisional bifurcation techniques and proximal stent optimization (POT), where post dilatation was typically performed.
Receives: Procedure: Percutaneous coronary intervention
ostial LAD (Ostial stenting(OS))Active comparatorOstial stenting of the LAD (OS) with no cross-over back to the LM.
Receives: Procedure: Percutaneous coronary intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of the clinical outcomes using different techniques in ostial LAD

    Evaluate the clinical outcomes in patients undergoing PCI for ostial LAD lesions

    The primary end points are:

    -Target vessel related myocardial infarction occuring within 48 hours defined by absolute rise in cardiac troponin (from baseline) ≥35 times upper reference limit plus 1 (or more) of the following criteria:

    • Flow-limiting angiographic complications.
    • New "substantial" loss of myocardium on imaging.

    Measured: 6 months

Secondary outcomes (3)
  1. Predictors of PCI success

    -Angiographic success in target vessel defined as residual stenosis ≤ 30% and TIMI flow grade 3

    Measured: 6 months

  2. Predictors of PCI success

    -Angiographic success in target vessel defined as SB angiographic success (residual stenosis ≤ 50% and TIMI flow grade 3).

    Measured: 6 months

  3. Predictors of ostial LAD PCI success

    -Procedural Success by doing successful PCI without in-hospital major clinical complications wihin one week of hospitalizaion

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jul 2023
  2. Study startJul 2023 (estimated)
  3. Primary completionJul 2025 (estimated)
  4. Study completionJul 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
72 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05933473
Sponsor's protocol ID
Coronary interventions
Status last verified
Jun 2023
First submitted
7 Apr 2023
Last updated
6 Jul 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018 Jun 12;137(24):2635-2650. doi: 10.1161/CIRCULATIONAHA.117.029289.

    PubMed 29891620
  • Rigatelli G, Zuin M, Baracca E, Galasso P, Carraro M, Mazza A, Lanza D, Roncon L, Daggubati R. Long-Term Clinical Outcomes of Isolated Ostial Left Anterior Descending Disease Treatment: Ostial Stenting Versus Left Main Cross-Over Stenting. Cardiovasc Revasc Med. 2019 Dec;20(12):1058-1062. doi: 10.1016/j.carrev.2019.01.030. Epub 2019 Jan 31.

    PubMed 30797760
  • Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol. 1993 Dec;22(7):2033-54. No abstract available.

    PubMed 8245363
  • Frangos C, Noble S, Piazza N, Asgar A, Fortier A, Ly QH, Bonan R. Impact of bifurcation lesions on angiographic characteristics and procedural success in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Arch Cardiovasc Dis. 2011 Apr;104(4):234-41. doi: 10.1016/j.acvd.2011.02.001. Epub 2011 Apr 19.

    PubMed 21624790

Questions about this trial

What is this clinical trial studying?

A study testing Percutaneous coronary intervention in people with Coronary Artery Disease, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Mohamed AN AbdEl-Reheem, MSC (01119535430, m.naserdrea3@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of the clinical outcomes using different techniques in ostial LAD (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05933473, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in